Class of 2026
For profound insights into apoptosis and its dysregulation in cancer, including uncovering BCL-2-mediated anti-apoptotic mechanisms, advancing pro-apoptotic therapies, and developing BH3 profiling to quantify mitochondrial priming and predict therapeutic response, an innovation that has fundamentally reshaped the design and clinical deployment of apoptosis-directed cancer treatments, including venetoclax.
*Full-length biography in development
[Institutional affiliations listed for Fellows reflect those held at the time of their induction into the AACR Academy.]